Hospices Civils de Lyon, Department of Urinary and Vascular Radiology, Hôpital Edouard Herriot, Lyon, France.
Nat Rev Clin Oncol. 2012 Dec;9(12):721-7. doi: 10.1038/nrclinonc.2012.136. Epub 2012 Aug 21.
Treatment of prostate cancer using high-intensity focused ultrasound (HIFU) focal therapy will become a reliable treatment option only if several conditions are fulfilled. These conditions concern patient selection, assessment of the tumour location and aggressiveness, evaluation of target tissue destruction, and detection of local recurrence or appearance of new tumours. Regarding patient selection, standard transrectal biopsies are not accurate enough and, although perineal template biopsies can detect tumours, they are invasive, expensive procedures, and there is a risk of incidental detection of insignificant cancers. In turn, multiparametric MRI is accurate for detecting and localizing high-grade (Gleason score ≥7) cancers and may provide non-invasive assessment of tumour aggressiveness. Moreover, contrast-enhanced imaging-ultrasonography or MRI-can assess post-HIFU tissue destruction and provide accurate detection of tumour recurrence, which is a key element for follow up. This Perspectives article will assess whether our current methods for cancer diagnosis, tissue targeting, and treatment follow up are accurate enough to allow the design of robust HIFU focal therapy protocols.
采用高强度聚焦超声(HIFU)局灶治疗前列腺癌,只有满足若干条件才能成为可靠的治疗选择。这些条件涉及患者选择、肿瘤位置和侵袭性评估、靶组织破坏评估以及局部复发或新肿瘤出现的检测。关于患者选择,标准经直肠活检不够准确,虽然会阴模板活检可以检测肿瘤,但这些方法具有侵袭性且费用高昂,并且存在偶然发现非重要性癌症的风险。相反,多参数 MRI 可准确检测和定位高级别(Gleason 评分≥7)癌症,并可提供肿瘤侵袭性的非侵入性评估。此外,对比增强成像超声或 MRI 可评估 HIFU 治疗后的组织破坏情况,并准确检测肿瘤复发,这是随访的关键要素。本文观点将评估我们目前用于癌症诊断、组织靶向和治疗随访的方法是否足够准确,以设计稳健的 HIFU 局灶治疗方案。